ROYALTY PHARMA AND FERRING PHARMACEUTICALS ENTER INTO US $500 MILLION ROYALTY AGREEMENT FOR NEW INTRAVESICAL GENE THERAPY ADSTILADRIN® (NADOFARAGENE FIRADENOVEC-VNCG)
This document is hosted externally.
Unless the owner has removed it from the web, you can access the full document via its original URL:
https://www.royaltypharma.com/wp-content/uploads/2023/12/591105ea-a88d-4061-9a8a-ce3a21f6f816.pdfUnless the owner has removed it from the web, you can access the full document via its original URL:
See similar contracts (1)
Alternatively, you can try searching for similar contracts:
